Buy Sustiva (Efavirenz) Online — Foundational NNRTI Antiretroviral for HIV-1 Infection Combination Therapy (Atripla Component)

📇 Sustiva product snapshot

📅 Efavirenz historical timeline

Early 1990s - Discovery at DuPont Merck

DuPont Merck Pharmaceutical Company chemists synthesize and screen benzoxazinone derivatives targeting HIV reverse transcriptase. Compound DMP 266 (later efavirenz) emerges as clinical candidate with potent activity and favorable pharmacokinetic profile.

1995 - Young et al. characterizes DMP 266

Young et al. publish initial characterization of DMP 266 antiviral activity and mechanism. High potency against HIV-1 reverse transcriptase and favorable resistance profile support advancement.

1996-1998 - Phase II and III clinical trials

Havlir et al. 1998 Phase II trial establishes efavirenz + NRTI backbone HIV suppression. Multiple registration studies including DMP 266-006 (Staszewski) support FDA submission.

September 17, 1998 - Sustiva FDA approval

Efavirenz approved by FDA as Sustiva - the third NNRTI (after nevirapine 1996 and delavirdine 1997). Approval based on virologic suppression evidence in combination with NRTI backbone.

1999 - DMP 266-006 landmark NEJM publication

Staszewski et al. publish DMP 266-006 pivotal trial in New England Journal of Medicine. Efavirenz + zidovudine + lamivudine shown superior to indinavir + zidovudine + lamivudine for tolerability and virologic response. Establishes efavirenz-based HAART as leading first-line option.

2001 - DuPont Pharmaceuticals to Bristol-Myers Squibb

Bristol-Myers Squibb acquires DuPont Pharmaceuticals for approximately 7.8 billion USD. Sustiva marketing transitions to BMS. Efavirenz becomes central component of BMS HIV portfolio.

2000s - HAART era dominance

Efavirenz + tenofovir + emtricitabine (or lamivudine) becomes standard first-line HIV regimen in DHHS and international guidelines. Millions of patients worldwide receive efavirenz-based combinations.

July 12, 2006 - Atripla FDA approval

Atripla (efavirenz + tenofovir DF + emtricitabine) approved as first single-tablet HIV regimen. Joint BMS-Gilead product. Transforms HIV therapy adherence and treatment simplification.

2013 - Dolutegravir era begins

SINGLE trial (Cahn 2013) demonstrates dolutegravir + abacavir + lamivudine non-inferior to efavirenz + tenofovir + emtricitabine. Beginning of the shift from efavirenz to integrase inhibitor-based first-line therapy.

2019 - ADVANCE study

Venter et al. publish ADVANCE (South Africa) showing dolutegravir-based regimens superior to efavirenz-based regimens in a resource-limited setting. Supports WHO transition guidance.

2019-present - WHO transition to dolutegravir

WHO consolidated guidelines recommend transition from efavirenz-based to dolutegravir-based first-line regimens globally. National HIV programs progressively shift, with efavirenz retained as alternative and in specific scenarios.

Present - Cipla generic ongoing

Cipla and other Indian generic manufacturers produce efavirenz for continued use in national HIV programs where alternative first-line therapy remains inaccessible or where specific patient factors favor efavirenz. WHO Essential Medicines status continues.

⚗️ Efavirenz chemical characteristics

🎯 Structural design significance

The trifluoromethyl group and cyclopropyl ethynyl substituent are critical for binding to the NNRTI pocket of HIV reverse transcriptase. The trifluoromethyl provides electron-withdrawing character that stabilizes the drug-enzyme interaction. The lipophilic aromatic scaffold ensures the molecule occupies the hydrophobic NNRTI binding pocket effectively.

The high lipophilicity (log P approximately 4.7) supports extensive tissue distribution including central nervous system penetration - which contributes both to therapeutic effect (CNS HIV control) and to the characteristic CNS adverse effects that shape efavirenz clinical practice.

🎯 Mechanism at a glance

NRTIs vs NNRTIs contrast: NRTIs (zidovudine, lamivudine, tenofovir) require intracellular phosphorylation to triphosphate form and then incorporation into growing viral DNA, causing chain termination. NNRTIs including efavirenz act directly on the enzyme without phosphorylation requirement. This mechanistic difference means NNRTIs are typically more rapidly active but do not incorporate into DNA.

The NNRTI binding pocket is present in HIV-1 reverse transcriptase but not in HIV-2 reverse transcriptase or in host cell polymerases - providing selective HIV-1 activity without affecting host cell replication or targeting HIV-2 meaningfully.

🔬 Detailed mechanism sequence

Step 1 - Cellular uptake

Efavirenz is highly lipophilic and enters target cells (CD4 T lymphocytes, macrophages, and other HIV-susceptible cells) by passive diffusion across the cellular membrane.

Step 2 - Direct enzyme targeting

Unlike NRTIs, efavirenz does not require phosphorylation. It acts directly on HIV-1 reverse transcriptase without intracellular activation.

Step 3 - NNRTI pocket binding

Efavirenz binds to a specific hydrophobic pocket approximately 10 angstroms from the reverse transcriptase catalytic site. This pocket is located in the p66 subunit and includes amino acid residues K101, K103, V106, Y181, Y188, G190, and W229 among others.

Step 4 - Enzyme conformational change

Binding induces conformational changes that displace the catalytic aspartate residues and prevent proper substrate positioning. The enzyme cannot correctly align incoming nucleotides for polymerization.

Step 5 - Reverse transcription blocked

HIV cannot convert its RNA genome into DNA. Without integration into host chromosome, HIV cannot establish productive infection. Viral load declines, and combination therapy achieves sustained suppression.

🎯 Key mechanistic features

Several features distinguish efavirenz mechanism from NRTIs and other antiretroviral classes:

• No phosphorylation required - direct enzyme targeting means efavirenz activity is not limited by intracellular kinase capacity
• HIV-1 specificity - the NNRTI pocket is only present in HIV-1; no meaningful HIV-2 activity
• Low genetic barrier to resistance - single mutations (particularly K103N) can confer high-level resistance because binding depends on precise pocket architecture
• No mitochondrial toxicity - efavirenz does not affect mitochondrial DNA polymerase gamma, avoiding the mitochondrial toxicity of some older NRTIs
• CNS penetration - high lipophilicity supports CNS drug exposure, which contributes both to therapeutic CNS HIV suppression and characteristic CNS adverse effects

📊 Efavirenz pharmacokinetic parameters

🎯 Practical PK implications for Sustiva prescribing

• Once-daily bedtime dosing - long half-life (40-55 hours) supports 24-hour dosing intervals; bedtime timing minimizes daytime CNS effect impact
• Missed dose tolerance - single missed doses have modest impact given long half-life; however consistent dosing supports adherence
• Empty stomach preferred - taking with food substantially increases exposure which can worsen CNS effects
• CYP2B6 slow metabolizers - approximately 15-25% of populations (higher in African ancestry) have 2-3-fold higher efavirenz exposure and more CNS effects
• Autoinduction - efavirenz induces its own metabolism to some extent, contributing to steady-state achievement
• Extensive drug interactions - CYP3A4 induction affects many concomitant medications (see section 18)

📋 FDA-approved indication framework

🌍 WHO Essential Medicines and global positioning

Efavirenz is on the WHO Model List of Essential Medicines for HIV treatment. WHO Prequalification of multiple generic efavirenz manufacturers supports global procurement. WHO consolidated guidelines through 2019 positioned efavirenz-based regimens as preferred first-line HIV therapy globally. Since 2019, WHO has recommended transition toward dolutegravir-based first-line regimens while retaining efavirenz as an alternative option for specific scenarios.

💊 Efavirenz combination era progression

🎯 Standard efavirenz-based HAART regimens

Efavirenz was combined with essentially every NRTI backbone during its dominance period:

• Efavirenz + zidovudine + lamivudine - pivotal DMP 266-006 regimen
• Efavirenz + tenofovir DF + emtricitabine - dominant HAART era combination; Atripla single tablet
• Efavirenz + tenofovir DF + lamivudine - widely used in resource-limited settings
• Efavirenz + abacavir + lamivudine - alternative in patients with tenofovir contraindications
• Efavirenz + didanosine + lamivudine - historical combination

🌟 Atripla clinical framework

Composition

Efavirenz 600 mg + tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg in one film-coated tablet

Dosing

One tablet once daily at bedtime, on empty stomach (fasting or at least 2 hours after evening meal); water only for administration

Historical significance

First single-tablet HIV regimen combining three antiretrovirals from two classes; established the STR (single-tablet regimen) paradigm that continues through modern regimens

Adherence transformation

Simplifying HAART from multiple tablets to one tablet dramatically improved adherence; studies documented substantially better virologic control with STR vs multi-tablet regimens

Dominance period

Atripla was the most widely prescribed HIV regimen in the US from 2006 through approximately 2013-2015 when integrase inhibitor single-tablet regimens emerged

Cost and access impact

Innovator Atripla launched at premium price; generic versions from multiple Indian manufacturers including Cipla have supported global HIV programs at substantially reduced cost

Modern positioning

Atripla is no longer preferred first-line therapy in most high-income guidelines. Continued use in stable patients; use in resource-limited settings; alternative when integrase inhibitors are contraindicated

🎯 Cipla generic Atripla-equivalent regimens

Cipla and other Indian generic manufacturers produce equivalent efavirenz + tenofovir DF + emtricitabine (or lamivudine) fixed-dose combinations at accessible prices. These generic products, procured through WHO Prequalification and national tender processes, have supported HIV programs across sub-Saharan Africa, South Asia, and Latin America. Millions of patients have received generic Atripla-equivalent combinations during the HAART era and continuing use.

🛡️ PEP framework and efavirenz historical role

Modern preferred PEP regimen

Tenofovir + emtricitabine + dolutegravir (or raltegravir) for 28 days after occupational or non-occupational HIV exposure. Preferred by CDC and WHO for tolerability, efficacy, and drug interaction profile.

Historical efavirenz PEP use

Efavirenz was occasionally included in PEP regimens during the HAART era when NRTI + PI regimens caused GI intolerance. However, CNS effects onset within days of starting efavirenz created major PEP adherence challenges.

Why efavirenz is not preferred for PEP

CNS effects appear rapidly after starting efavirenz - dizziness, sleep disruption, mood changes within days. These effects can compromise the 28-day PEP adherence that is essential for prevention efficacy. Modern integrase inhibitor PEP has substantially better tolerability during the 28-day window.

Timing critical regardless of regimen

PEP effectiveness depends on rapid initiation - ideally within 2 hours of exposure, definitely within 72 hours. Delay beyond 72 hours substantially reduces efficacy. Regimen selection is secondary to time to initiation.

Non-occupational PEP (nPEP)

Similar principles apply to non-occupational HIV exposure through sexual contact or shared injection equipment. Modern nPEP uses tenofovir-based integrase inhibitor regimens. Efavirenz is essentially not used.

Resource-limited settings

In settings where preferred PEP regimens are unavailable, efavirenz-containing PEP may be an acceptable alternative per WHO guidance. Practical use has become uncommon as integrase inhibitor generics have become widely available globally.

🎯 Pre-exposure prophylaxis (PrEP) - not efavirenz

Pre-exposure prophylaxis for HIV-negative individuals at ongoing risk uses tenofovir + emtricitabine (Truvada) or tenofovir alafenamide + emtricitabine (Descovy), not efavirenz. Long-acting injectable cabotegravir has emerged as an additional PrEP option. Efavirenz has not been developed as PrEP. Understanding this distinction (PEP vs PrEP) clarifies efavirenz narrow HIV prevention role.

🔄 Modern efavirenz role framework

Continuation in stable patients

Many patients on stable efavirenz-containing regimens (including Atripla or component-based combinations) doing well with virologic suppression continue their regimen. Regimen switching for the sake of switching is not usually indicated.

Resource-limited settings

National HIV programs where cost, availability, or established clinical infrastructure favor efavirenz over dolutegravir-based regimens continue efavirenz use. Cipla and other Indian generic manufacturers produce affordable efavirenz supporting these programs.

Alternative when integrase inhibitors contraindicated

Some patients cannot use dolutegravir or other integrase inhibitors due to hypersensitivity, drug interactions, or specific clinical factors. Efavirenz may be a substitute NNRTI in these scenarios.

TB coinfection considerations

Efavirenz can be used with rifampin (a CYP3A4 inducer) in HIV/TB coinfection with dose adjustment; some historical preference for this combination reflects manageable pharmacokinetic interactions.

Not preferred for initial adult therapy in modern guidelines

Current DHHS, IAS-USA, EACS, and BHIVA guidelines recommend dolutegravir-based or bictegravir-based regimens for initial adult HIV therapy in most patients. Efavirenz is listed as alternative rather than preferred option.

Specific clinical scenarios

Some patients with specific comorbidities or preferences may benefit from efavirenz-based therapy. Individualized decision-making with specialist involvement supports appropriate selection.

🎯 Why efavirenz retreated from routine use

Several factors drove the shift away from efavirenz as first-line first NNRTI choice:

• CNS effects burden - 40-50% of patients experience CNS effects that affect quality of life
• Neuropsychiatric concerns - suicide ideation black box warning; depression association
• Lower genetic barrier to resistance - single K103N mutation confers high-level resistance
• CYP450 interactions - CYP3A4 induction complicates concomitant medication use
• Modern integrase inhibitors offer improvements - dolutegravir has fewer CNS effects, higher genetic barrier, cleaner interaction profile
• Once-daily dosing convenience - both efavirenz and dolutegravir are once-daily; dolutegravir has better daytime tolerability

🌍 Global access framework for efavirenz

WHO Essential Medicines status

Efavirenz remains on the WHO Model List of Essential Medicines for HIV treatment. This status supports procurement through UN agencies, the Global Fund, and national procurement systems.

Generic availability

Cipla, Hetero, Aurobindo, Mylan, and other Indian generic manufacturers produce efavirenz alone and in fixed-dose combinations (Atripla-equivalents, other combinations) at accessible prices. WHO Prequalification of multiple products supports quality-assured procurement.

National HIV program integration

Many national HIV programs in Africa, South Asia, and Latin America continue efavirenz-containing regimens as component options within their formularies. This reflects cost, familiarity, and established supply chains as well as clinical practice patterns.

Transition toward dolutegravir-based regimens

WHO recommendations and national programs are progressively transitioning toward tenofovir + lamivudine + dolutegravir first-line regimens. Efavirenz progressively transitions to alternative option status. The transition has been managed carefully to avoid regimen interruptions for individual patients on stable therapy.

ADVANCE study South Africa

The ADVANCE study (Venter 2019) directly compared dolutegravir-based vs efavirenz-based regimens in South Africa. Findings supported dolutegravir preference including improved virologic suppression rates. This evidence has substantially informed the ongoing transition in resource-limited settings.

HIV/TB coinfection considerations

In HIV/TB coinfection where rifampin (CYP3A4 inducer) is prescribed for tuberculosis, efavirenz has been preferred historically because manageable dose adjustment allows co-administration. Modern dolutegravir + rifampin management is also feasible with dose adjustment, but efavirenz retains some advantage in this specific scenario.

Ongoing training and clinical infrastructure

Clinicians in national HIV programs are familiar with efavirenz CNS effect monitoring and management. This established clinical experience supports continued safe use during progressive transition to newer regimens.

🎯 The sub-Saharan African HIV program context

Sub-Saharan Africa carries the largest global HIV burden. National programs in South Africa, Kenya, Uganda, Nigeria, and many other countries have provided combination antiretroviral therapy to millions of patients over the past two decades. Efavirenz-based regimens were the workhorses of these programs for many years. Progressive transition to tenofovir + lamivudine + dolutegravir has been underway since 2019, but efavirenz retains presence in alternative regimens and continuing use in specific patient populations. The transition has been managed to avoid regimen interruptions that could compromise treatment continuity for individual patients.

📈 Cipla generic HIV framework

Cipla Limited overview

Founded 1935 by Khwaja Abdul Hamied; led by Yusuf Hamied from 1972 through 2013. One of the world largest generic pharmaceutical manufacturers with substantial HIV portfolio spanning NRTIs (zidovudine, lamivudine, tenofovir), NNRTIs (efavirenz, nevirapine), and integrase inhibitors (dolutegravir).

2001 HIV access breakthrough

In February 2001, Yusuf Hamied announced that Cipla would offer generic combination antiretroviral therapy at approximately 1 USD per patient per day - a dramatic reduction from the roughly 10,000 USD annual price of branded HIV therapy at the time. This announcement transformed global HIV treatment access.

Efavirenz generic manufacture

Cipla began producing generic efavirenz shortly after Indian patent law changes permitted generic manufacture. Multiple Cipla efavirenz products including standalone 600 mg tablets and fixed-dose combinations (efavirenz + tenofovir + lamivudine or emtricitabine) are marketed globally.

Quality frameworks

Cipla manufacturing facilities are approved by the US FDA, EMA, WHO Prequalification, and multiple national regulatory authorities. Cipla generic efavirenz has demonstrated bioequivalence to the innovator BMS Sustiva product through standard pharmacokinetic studies.

Access-oriented distribution

Cipla generic products are procured through UN agencies (WHO, UNITAID), the Global Fund to Fight AIDS Tuberculosis and Malaria, national tender processes, and NGO health programs. This distribution framework has supported HIV programs across sub-Saharan Africa, South Asia, and Latin America.

Continued innovation portfolio

Cipla continues to manufacture generic HIV medications including newer options like dolutegravir. This progressive portfolio expansion supports the WHO-recommended transition to dolutegravir-based first-line regimens while maintaining efavirenz availability for continued and alternative use.

🎯 Bioequivalence and quality assurance

Cipla generic efavirenz demonstrates bioequivalence to the innovator BMS Sustiva product. Peak concentration, area under the curve, and time to peak concentration fall within the standard 80-125% bioequivalence limits accepted by regulators worldwide. Clinical outcomes with Cipla generic efavirenz match innovator product performance. Multiple third-party quality assessments and WHO Prequalification support this quality equivalence.

📊 Sustiva adult dosing framework

📋 Administration essentials for tolerability

• Bedtime timing minimizes daytime effects - vivid dreams and dizziness occur during sleep rather than affecting daily function
• Empty stomach reduces peak concentration - lower Cmax means less severe CNS effect intensity
• Consistent daily timing supports adherence - link to bedtime routine (before brushing teeth, after last meal, before bed) for reliability
• Combination partner medications timing - if NRTI backbone is separate from Sustiva, coordinate timing per each drug requirement
• Adherence critical from initiation - non-adherence in first months can select K103N resistance requiring regimen change

🧒 Pediatric weight-based efavirenz dosing

🎯 Pediatric administration considerations

• Capsule sprinkle for infants - capsule contents may be opened and sprinkled on small amount of soft food (yogurt, applesauce, apple sauce, formula, or breast milk) if child cannot swallow capsules
• Bedtime timing applies to children - reduces daytime CNS effect impact on schooling and activities
• Empty stomach where feasible - same as adult recommendation to reduce CNS effect intensity
• Modern pediatric regimens - dolutegravir + tenofovir + emtricitabine has become preferred pediatric first-line in high-income settings
• Vertical transmission context - most pediatric HIV in high-income countries results from vertical transmission from HIV-positive mothers

👴 Considerations for older adults on Sustiva

CNS effect impact greater

Efavirenz CNS effects (dizziness, cognitive concerns, sleep disruption) may be more impactful in older adults. Falls risk, driving safety, and cognitive function considerations may favor alternative NNRTIs or integrase inhibitors when clinically appropriate.

Polypharmacy interaction burden

Older adults often take multiple medications for cardiovascular, metabolic, and other chronic conditions. Efavirenz CYP3A4 induction affects many concomitant medications (statins, calcium channel blockers, some antidepressants, warfarin). Comprehensive medication reconciliation is essential.

Renal function assessment

Age-related renal function decline is expected. Efavirenz itself requires minimal renal adjustment, but the tenofovir DF component of common Atripla combinations does require renal dose adjustment. Serum creatinine may underestimate GFR decline given reduced lean muscle mass.

Hepatic function considerations

Age-related hepatic changes may affect efavirenz metabolism. Baseline and periodic hepatic function testing supports safe therapy. Any suggestive symptoms or lab abnormalities warrant workup.

Bone density and metabolic factors

Efavirenz may affect vitamin D metabolism. Bone density concerns particularly relevant with tenofovir DF-containing combinations. Modern integrase inhibitor + tenofovir alafenamide combinations offer better bone density profile.

Cognitive support and adherence

Cognitive impairment may affect adherence. Simplified regimens (single-tablet Atripla, or modern integrase inhibitor STRs), pill organizers, caregiver involvement, and phone reminders support ongoing adherence.

Cure benefit persists at any age

Effective HIV therapy improves survival and quality of life across all ages. When Sustiva-containing therapy is indicated and tolerated, benefits outweigh challenges with appropriate monitoring. Age alone should not exclude appropriate treatment.

🫀 Renal impairment framework for Sustiva combination therapy

🎯 Fixed-dose combination limitation

Atripla (efavirenz + tenofovir DF + emtricitabine) cannot be split or dose-adjusted for renal impairment. When creatinine clearance falls below thresholds requiring tenofovir DF adjustment, patients must switch from Atripla to separate efavirenz, tenofovir DF (with dose adjustment), and emtricitabine (with dose adjustment) tablets. Alternatively, transition to a tenofovir alafenamide (TAF)-containing regimen or a non-tenofovir alternative supports renal safety.

🪶 Hepatic impairment framework for Sustiva

Mild to moderate impairment (Child-Pugh A or B)

Standard 600 mg once daily can be used with clinical monitoring. Assess for changes in hepatic enzymes during therapy. Alternative NNRTI or integrase inhibitor may be preferred if hepatic function is borderline.

Severe impairment (Child-Pugh C)

Limited safety data. Clinical judgment recommends caution given potential for altered metabolism and pharmacokinetic changes. Alternative HIV regimens (integrase inhibitor-based) may be preferred. Specialist consultation supports individualized decision-making.

HIV/HBV coinfection

Efavirenz has no anti-HBV activity. HIV/HBV coinfected patients require tenofovir + lamivudine (or emtricitabine) for HBV coverage regardless of efavirenz. Atripla combines efavirenz with these NRTIs, providing HBV coverage. Regimen switching must maintain HBV-active therapy to prevent HBV flare.

HIV/HCV coinfection

Modern HCV cure with sofosbuvir-based DAAs is standard. Efavirenz can be co-administered with sofosbuvir-based regimens with attention to interactions (efavirenz CYP3A4 induction may affect some HCV DAA exposures). Coordination with hepatology supports appropriate DAA selection.

Hepatic transaminase elevation during therapy

Efavirenz can cause hepatic transaminase elevations. Consider drug-induced liver injury, HBV or HCV activity, alcohol effects, and other causes. Progressive or symptomatic elevations warrant workup and possible therapy modification.

Severe hepatic reactions

Rare severe hepatic reactions have been reported including hepatic failure. Immediate discontinuation warranted for progressive hepatic dysfunction or clinical hepatitis signs.

🎯 Pre-treatment hepatic assessment

Baseline assessment includes comprehensive metabolic panel with hepatic enzymes and albumin; PT/INR; HBsAg, anti-HBc, anti-HBs screening (mandatory before HIV therapy); HCV RNA screening; assessment for hepatic steatosis, cirrhosis, or coexisting viral hepatitis; alcohol use assessment. Baseline abnormalities may warrant hepatology consultation before initiating Sustiva.

🧬 Efavirenz interactions - drugs affected by CYP3A4 induction

🧬 Drugs affecting efavirenz metabolism

🎯 CYP2B6 pharmacogenomic variability

CYP2B6 genetic polymorphisms (516G>T, 983T>C, and others) create slow, intermediate, and rapid metabolizer phenotypes. Slow metabolizers (approximately 15-25% of populations, higher frequency in African ancestry populations) have 2-3-fold higher efavirenz exposure and more prominent CNS effects. Rapid metabolizers may have subtherapeutic exposure. Pharmacogenomic testing is not routinely performed but may inform difficult tolerability scenarios.

🤰 Pregnancy considerations framework

Historical FDA Category D classification

Efavirenz was classified as Pregnancy Category D based on animal studies showing neural tube defect signals and limited early human data. Historical guidance advised avoidance in first trimester of pregnancy. Under the current PLLR (Pregnancy and Lactation Labeling Rule) narrative labeling, this categorical designation has been replaced with narrative descriptions.

Antiretroviral Pregnancy Registry data

Substantial accumulated first-trimester exposure data through the Antiretroviral Pregnancy Registry has generally not shown increased birth defect rates above baseline population rates. This has supported revised risk assessment permitting efavirenz continuation in pregnancy when clinically appropriate.

Modern guideline positioning

WHO consolidated antiretroviral guidelines (since 2019 update) permit efavirenz use in pregnancy including first trimester. US Perinatal HIV Guidelines position efavirenz as alternative rather than preferred. Preferred maternal ART typically is dolutegravir-based regimens for both pregnancy planning and pregnancy therapy.

Dolutegravir preferred first-line

Modern preferred first-line HIV therapy in pregnancy is tenofovir + emtricitabine + dolutegravir. This preference reflects superior tolerability, higher genetic barrier to resistance, and cleaner interaction profile. Earlier Tsepamo signal about periconceptional dolutegravir and neural tube defects has been reconsidered as follow-up data accumulated.

Placental transfer

Efavirenz crosses the placenta - cord-to-maternal ratio approximately 0.5. Fetal exposure occurs at meaningful levels. This contributes to both potential fetal effects and therapeutic maternal-fetal HIV suppression.

Perinatal HIV prevention framework

The overarching goal in pregnancy is achieving and maintaining maternal HIV RNA suppression to prevent vertical transmission. When achieved through effective combination therapy, vertical transmission rates fall to well under 1%. Efavirenz-based therapy can achieve this goal, though modern integrase inhibitor-based regimens are preferred.

Contraception importance

Given efavirenz substantial reduction of oral contraceptive effectiveness (discussed in section 18), reliable contraception through barrier methods, IUD, or long-acting reversible contraception is essential in women of reproductive potential on Sustiva who wish to avoid pregnancy.

🎯 Practical framework for women of reproductive potential

Modern management approach:

• Assess pregnancy potential and reproductive plans before starting therapy
• Prefer dolutegravir-based first-line regimens for initial therapy when possible
• For women already on stable efavirenz-containing regimens: continuation is typically appropriate
• For women becoming pregnant on efavirenz: continue current regimen unless clinical reason for change
• Assess and manage contraception during Sustiva therapy given oral contraceptive interaction
• Enroll pregnancies in Antiretroviral Pregnancy Registry to support ongoing safety data collection

🍼 Breastfeeding framework for HIV-positive mothers on Sustiva

HIV-positive mothers in high-income settings

Current US and European guidelines recommend against breastfeeding by HIV-positive mothers because safe formula feeding is universally available and eliminates postnatal HIV transmission risk. Even with suppressed maternal viral load, low-level HIV transmission through breast milk cannot be entirely excluded.

HIV-positive mothers in resource-limited settings

WHO guidelines recommend exclusive breastfeeding for 6 months followed by mixed feeding while continuing effective maternal antiretroviral therapy, when formula feeding is not safely accessible. Maternal viral suppression through combination therapy dramatically reduces breast milk HIV transmission risk.

Efavirenz in breast milk

Efavirenz passes into breast milk. Estimated milk-to-plasma ratio approximately 0.5-1.0. Infant plasma efavirenz concentrations detectable but generally modest. Long-term effects on breastfed infants have been evaluated in observational cohorts without evidence of adverse effects specifically attributable to efavirenz breast milk exposure.

Combined maternal and infant considerations

Infants born to HIV-positive mothers on efavirenz may receive both breast milk efavirenz exposure and direct neonatal prophylaxis (typically zidovudine syrup). Combined exposure has been studied without evidence of additive toxicity beyond expected effects.

Shared decision-making

Modern guidelines increasingly emphasize shared decision-making, particularly where cultural, emotional, and practical considerations weigh heavily. Even in high-income settings, some HIV-positive women with sustained viral suppression on Sustiva express strong preference for breastfeeding, and non-judgmental support with enhanced monitoring may be appropriate.

Infant monitoring during breastfeeding

Infants breastfed by HIV-positive mothers on efavirenz receive continued HIV testing at established intervals until 6-12 weeks after complete cessation of breast milk exposure. Some settings include continued infant antiretroviral prophylaxis throughout breastfeeding.

📋 Common efavirenz adverse effects

🎯 Historical tolerability comparison

Historical HAART era (1998-2013): efavirenz + tenofovir + emtricitabine (Atripla) was widely used with tolerability accepted despite CNS effects. Patients often adapted to CNS effects within first 2-3 months. Discontinuation for tolerability approximately 10-15% within first year.

Modern integrase inhibitor era (2013-present): dolutegravir and bictegravir combinations have substantially better tolerability profiles. Discontinuation for tolerability approximately 1-3% in modern trials. This tolerability gap drives modern preference for integrase inhibitor first-line therapy.

The tolerability difference is one of the primary reasons for the transition from efavirenz to integrase inhibitor first-line therapy in modern guidelines.

🚨 Sustiva safety profile at a glance

🧠 Efavirenz CNS effects characterization

🎯 CNS effects mechanism

Efavirenz has substantial CNS penetration (approximately 0.7-1.2% of plasma total concentration in CSF, with higher free/unbound fraction). The molecule likely interacts with various CNS receptors including serotonin, GABA, and cannabinoid systems. Peak CNS effects typically correlate with peak plasma concentrations, which is why:

• Bedtime dosing - allows peak concentration to occur during sleep
• Empty stomach - avoids food-induced 30-80% AUC increase that worsens effects
• CYP2B6 slow metabolizers - experience more severe effects due to higher exposure
• Tolerance development - most patients develop CNS tolerance over 2-3 months

📋 CNS effects management framework

Bedtime timing

Take Sustiva at bedtime to allow peak effects during sleep. Vivid dreams may occur but daytime functional impact is minimized. This is the single most important management strategy.

Empty stomach administration

Take on empty stomach (fasting or at least 2 hours after evening meal, water only for administration). Food increases exposure substantially and worsens CNS effects.

Set expectations at initiation

Counsel patients before starting therapy: CNS effects are common (40-50%), typically start within first days, and usually improve substantially by 2-3 months. Setting these expectations dramatically improves patient experience.

Driving and safety considerations

Advise caution with driving, operating machinery, or performing tasks requiring alertness during the first weeks of therapy. Dizziness and cognitive effects can affect safety.

Sleep aids as needed

Short-term hypnotics may be considered for severe insomnia in select patients. Melatonin may help sleep onset. Avoid additional CNS depressants that could compound effects.

Alcohol avoidance

Alcohol can worsen efavirenz CNS effects. Advise moderation or avoidance during initial adaptation period.

Dose reduction option

Efavirenz 400 mg once daily (ENCORE1 evidence) provides non-inferior efficacy with reduced CNS effect burden. May be considered for patients experiencing prominent CNS effects but wishing to continue efavirenz.

Alternative therapy consideration

Patients with severe or persistent CNS effects beyond 2-3 months typically benefit from switching to integrase inhibitor-based regimens (dolutegravir + tenofovir + emtricitabine or bictegravir-based STR). Modern alternatives have dramatically better CNS tolerability.

⚠️ FDA Warning: Serious psychiatric symptoms

Serious psychiatric adverse experiences have been reported in patients treated with Sustiva. These include severe depression, suicidal ideation or attempts, aggressive behavior, paranoid reactions, and manic reactions. Patients with a history of psychiatric disorders may be at greater risk. Advise patients that if they experience severe psychiatric adverse experiences, they should contact their healthcare provider immediately.

🧠 Neuropsychiatric effects framework

📋 Neuropsychiatric management framework

Pre-treatment psychiatric screening

Assess baseline depression, anxiety, and psychiatric history before starting therapy. Patients with active untreated severe psychiatric conditions may benefit from mental health optimization before initiating Sustiva, or alternative HIV therapy may be more appropriate.

Risk factors for neuropsychiatric events

Prior psychiatric history (particularly depression, suicidal ideation, or psychosis); active substance use; social isolation; recent major life stressors; CYP2B6 slow metabolizer status; concomitant medications with CNS effects.

Ongoing psychiatric monitoring

Structured mental health screening at follow-up visits during first 6 months of therapy. Standard depression screening tools (PHQ-2, PHQ-9) support clinical assessment. Direct questioning about mood, sleep, suicidal thoughts.

Serious events response

Any expression of suicidal ideation, homicidal ideation, severe depression, paranoia, or psychosis warrants immediate psychiatric evaluation. Sustiva discontinuation and switch to alternative HIV therapy is typically appropriate. Coordination with psychiatric services essential.

Modern preference for alternative therapy

Patients with significant psychiatric history should typically receive dolutegravir-based or bictegravir-based first-line HIV therapy rather than efavirenz. This preference reflects the neuropsychiatric burden of efavirenz and the improved tolerability of modern integrase inhibitors.

Post-cure improvement

Efavirenz-associated psychiatric effects typically improve or resolve after discontinuation. Recovery timeframe depends on individual factors including CYP2B6 metabolism and effect severity.

🧪 Cutaneous reactions framework

Mild non-specific rash

Occurs in 10-15% of Sustiva-treated patients. Typically morbilliform or maculopapular pattern. Onset usually in first 2-4 weeks. Often self-limited with continued therapy. Symptomatic management with antihistamines and topical corticosteroids as needed.

Mild pruritus

Itching with or without visible rash. Emollients, oral antihistamines for symptomatic relief. Sedating antihistamines at bedtime if itching interferes with sleep.

Severe cutaneous reactions - rare

Stevens-Johnson syndrome and rarely toxic epidermal necrolysis reported. Presenting features include mucosal involvement, blistering, systemic symptoms, and rapidly progressive skin findings. Any of these require immediate treatment discontinuation and specialist referral.

DRESS syndrome

Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported very rarely with efavirenz. Presents with rash, fever, lymphadenopathy, hepatic transaminase elevation, and eosinophilia. Requires immediate discontinuation and hospitalization.

Photosensitivity

Enhanced sun sensitivity has been reported occasionally. Standard sun protection with broad-spectrum SPF 30 or higher sunscreen, protective clothing prudent during therapy.

Timing considerations

Most rash occurs within the first 2-4 weeks of therapy. Rash appearing later in therapy course is less common and warrants evaluation for other causes (concurrent medications, viral illness, environmental exposures).

🎯 Warning signs requiring urgent evaluation

Any of the following features in a Sustiva-treated patient warrant immediate discontinuation and specialist evaluation:

• Rash with fever (over 38.5 C)
• Mucosal involvement (mouth, eyes, genitals)
• Blistering or skin sloughing
• Systemic symptoms - lymphadenopathy, hepatic enzyme elevation, eosinophilia
• Rapidly progressive skin findings
• Facial swelling or angioedema
• Difficulty breathing or swallowing

🪶 Hepatic effects framework

Mild transaminase elevations

Occur in 5-15% of Sustiva-treated patients. Usually asymptomatic. Do not typically require dose modification. Monitor with periodic hepatic function testing.

Moderate to severe transaminase elevations

ALT or AST elevation over 5 times upper limit of normal occurs in approximately 2-4% of patients. Assess for other causes (viral hepatitis activity, alcohol, other medications) before attributing to efavirenz. Consider therapy modification for progressive elevation.

Severe hepatic reactions

Rare severe hepatic reactions including hepatic failure have been reported. Immediate discontinuation warranted for progressive hepatic dysfunction or clinical hepatitis signs.

HBV/HCV coinfection considerations

HIV/HBV coinfection: efavirenz has no anti-HBV activity. Combination regimen must include tenofovir + lamivudine or emtricitabine for HBV coverage. HIV/HCV coinfection: modern DAA cure with sofosbuvir-based regimens standard. Efavirenz can be co-administered with attention to CYP3A4 interactions.

Alcohol and other hepatotoxic contributors

Alcohol use, other hepatotoxic medications, and non-alcoholic fatty liver disease can contribute to hepatic effects. Assessment and management of contributors is essential during Sustiva therapy.

Assessment approach for elevations

Consider drug-induced liver injury, HBV or HCV activity, alcohol effects, other medications, and non-alcoholic fatty liver disease when transaminases rise. Do not automatically attribute to efavirenz without workup for other contributors.

⚖️ Metabolic effects framework

Lipid changes on efavirenz

Total cholesterol typically rises 5-15%. LDL cholesterol may rise similarly. Triglycerides may rise 10-25%. HDL cholesterol often rises modestly (which is favorable). These changes are usually modest but contribute to cardiovascular risk assessment.

Lipid monitoring

Baseline fasting lipid panel before starting Sustiva. Annual monitoring during ongoing therapy. Address modifiable risk factors (diet, exercise, smoking cessation, blood pressure). Statin therapy per cardiovascular guidelines when indicated.

Insulin sensitivity considerations

Efavirenz may have modest effects on insulin sensitivity and glucose metabolism. Baseline and periodic fasting glucose or HbA1c assessment supports diabetes screening. Standard diabetes management per guidelines when indicated.

Statin interaction considerations

Efavirenz CYP3A4 induction reduces exposure of simvastatin, lovastatin, and pitavastatin substantially. Preferred statins with efavirenz include atorvastatin (with dose adjustment) and rosuvastatin. Pharmacist consultation supports appropriate statin selection.

HIV lipodystrophy syndrome

Historical HIV lipodystrophy (fat redistribution, insulin resistance) was mostly driven by thymidine NRTIs (zidovudine, stavudine) and older protease inhibitors. Efavirenz contributes minimally to this syndrome. Modern regimens including efavirenz combinations rarely produce clinical lipodystrophy.

Modern era comparison

Modern integrase inhibitor-based regimens (dolutegravir) have relatively favorable lipid profiles compared to efavirenz. Bictegravir and dolutegravir combinations generally have less lipid impact. This favorable metabolic profile is one advantage of modern integrase inhibitor first-line therapy.

🫀 Cardiac considerations framework

QTc prolongation

Efavirenz can cause modest QTc prolongation - typically less than 10 ms increase from baseline in most patients. This effect is usually clinically insignificant in patients without other risk factors. Concurrent QT-prolonging medications amplify the effect.

Risk factors for arrhythmia

Congenital long QT syndrome, heart failure, bradycardia, electrolyte disorders (hypokalemia, hypomagnesemia), older age, female sex, concomitant QT-prolonging medications (some antibiotics, antipsychotics, antidepressants, methadone).

Baseline cardiac assessment

Baseline ECG in patients with cardiovascular history, arrhythmia risk factors, or on concurrent QT-prolonging medications. Assessment of underlying cardiac disease supports appropriate patient selection.

Concurrent QT-prolonging medications

Structured review for concurrent QT-prolonging drugs. Common examples include fluoroquinolones, macrolides, ondansetron, some antipsychotics, methadone (especially high doses), amiodarone. Interaction assessment is important for combined effect.

Modern integrase inhibitor comparison

Dolutegravir, bictegravir, and other modern integrase inhibitors have minimal QTc effects. This favorable cardiac profile is one of the advantages of modern first-line therapy in patients with cardiac considerations.

Electrolyte management

Maintain normal potassium and magnesium levels. Address underlying causes of electrolyte disturbances (diuretics, GI losses, malnutrition). Correction of electrolyte abnormalities reduces arrhythmia risk.

🎯 Warning signs requiring cardiac evaluation

Patients on Sustiva should report:

• Palpitations or racing heartbeat
• Near-syncope or syncope
• Chest discomfort
• Progressive dyspnea (especially exertional)
• New or worsening cardiac symptoms of any kind

⚡️ Convulsion and neurological considerations

Convulsion incidence

Uncommon (under 1% of general Sustiva population). Higher in patients with pre-existing seizure history, structural CNS disease, or on concurrent proconvulsant medications.

Baseline seizure history assessment

Detailed neurological history at baseline. Prior seizures, seizure disorders, CNS trauma, brain surgery, structural CNS disease. Seizure history is not an absolute contraindication but warrants specialist input for treatment planning.

Concurrent medications

Assess for concurrent medications that lower seizure threshold: some antibiotics (fluoroquinolones), tramadol, bupropion, various antidepressants and antipsychotics. Combinations may increase seizure risk.

Anticonvulsant interactions

Phenytoin, phenobarbital, and carbamazepine can induce efavirenz metabolism unpredictably. Newer anticonvulsants (levetiracetam, lamotrigine, gabapentin) generally have fewer interactions with efavirenz and may be preferred for patients requiring seizure control on efavirenz.

Withdrawal seizures

Sudden efavirenz discontinuation is not typically associated with withdrawal seizures. However, in patients with underlying seizure disorders, continuity of care and communication between HIV and neurology providers is important during any regimen changes.

Response to new seizures

New seizures during Sustiva therapy warrant urgent neurological evaluation. Consider drug effect, CNS opportunistic infection (particularly in patients with low CD4), metabolic causes, and other etiologies. Sustiva discontinuation may be warranted depending on assessment.

🦴 Bone and vitamin D considerations

Efavirenz effect on vitamin D metabolism

Efavirenz induces CYP24A1 which catabolizes 25-hydroxyvitamin D. This results in modestly reduced serum 25-OH vitamin D levels. Clinical significance is modest but contributes to overall bone health considerations.

Combined Atripla effects on bone

Atripla contains tenofovir DF which reduces bone mineral density independently of efavirenz. Combined effects may contribute to accelerated bone loss over years of therapy. Modern tenofovir alafenamide (TAF)-containing regimens have substantially better bone density profile.

Fracture risk in HIV populations

People with HIV have modestly elevated fracture risk compared to age-matched controls. Multifactorial contributors include chronic inflammation, antiretroviral effects, lifestyle factors, and comorbidities. HIV itself and specific antiretrovirals both contribute.

Baseline vitamin D assessment

Baseline 25-OH vitamin D level in patients with risk factors (older age, dark skin pigmentation, limited sun exposure, dietary insufficiency). Supplementation for identified deficiency per standard guidelines (typically 1000-2000 IU daily for deficiency correction, then maintenance).

Bone density assessment

DXA scan for bone density assessment in high-risk patients: post-menopausal women, older men, those on long-term tenofovir DF-containing regimens, patients with fracture history, chronic corticosteroid use. Timing per standard guidelines.

Modifiable risk factor management

Standard bone health interventions: adequate dietary calcium (1000-1200 mg/day), vitamin D supplementation for deficiency, weight-bearing exercise, fall risk reduction, smoking cessation, alcohol moderation. Fracture history warrants secondary prevention including bisphosphonate consideration.

Modern alternative options

Patients with significant bone density concerns may benefit from switching from Atripla to a tenofovir alafenamide-based regimen (Biktarvy, Genvoya). Biktarvy uses bictegravir (integrase inhibitor) which has no effect on vitamin D metabolism.

🔬 False-positive cannabinoid screening framework

Mechanism

Efavirenz metabolites (8-hydroxy-efavirenz and other conjugates) cross-react with immunoassay-based cannabinoid urine screening tests. The mechanism involves structural similarity of the metabolites to cannabinoid antibody binding sites. This is a well-documented and reproducible phenomenon.

Frequency

Regular occurrence in Sustiva-treated patients. Positive screens can persist for weeks after efavirenz discontinuation due to prolonged metabolite clearance.

Confirmatory testing

Gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) confirmatory testing distinguishes true cannabinoid use from efavirenz cross-reactivity. Confirmatory testing does not detect efavirenz metabolites as cannabinoids.

Practical implications for patients

Patients starting Sustiva should be counseled about this phenomenon. Written documentation from prescribing physician noting efavirenz use and cross-reactivity potential is helpful for employment or legal screenings. Confirmatory testing should be requested when possible.

Employment screening

Employment drug screening programs may require additional documentation or confirmatory testing. Occupational medicine specialists can support appropriate accommodation. Some HIV specialty pharmacies provide patient advocacy documentation.

Legal or forensic screening

In legal or forensic contexts, efavirenz cross-reactivity may create serious complications if not properly addressed. Patients in such situations may benefit from consultation with legal counsel and possible therapy switching if the cross-reactivity creates unmanageable problems.

🛡️ IRIS framework

Definition and mechanism

Paradoxical worsening of clinical status shortly after starting effective antiretroviral therapy, reflecting recovering immune response to previously suppressed pathogens. Timing typically within weeks to months of starting therapy.

Common IRIS presentations

Tuberculosis reactivation with worsening pulmonary or nodal disease; cryptococcal meningitis unmasking; cytomegalovirus retinitis; mycobacterium avium complex; herpes zoster; hepatitis B or C flare; progressive multifocal leukoencephalopathy unmasking; Kaposi sarcoma progression.

Risk factors

Low CD4 count at antiretroviral therapy initiation (particularly under 50 cells), presence of subclinical opportunistic infections, rapid CD4 recovery, high pre-treatment viral load.

Not efavirenz-specific

IRIS reflects the underlying immune reconstitution from effective HIV therapy rather than a specific Sustiva effect. Any effective antiretroviral regimen including modern integrase inhibitor-based therapy can trigger IRIS.

Management principles

Continue antiretroviral therapy in most cases. Treat the specific unmasked opportunistic infection appropriately. Corticosteroids may be used in severe presentations. Discontinuing antiretroviral therapy is rarely appropriate and would allow HIV to worsen again.

Prevention strategies

Screening for latent tuberculosis, cryptococcal antigen (in patients with CD4 under 100 in endemic areas), CMV retinitis on funduscopy, and HBV/HCV serology before starting antiretroviral therapy. Treating identified subclinical infections before or shortly after starting antiretroviral therapy reduces IRIS risk substantially.

🧬 Efavirenz resistance framework

🎯 Modern practical implications

The low genetic barrier to efavirenz resistance has several important implications:

• Adherence critical - non-adherence in first months can select K103N requiring regimen change
• Never monotherapy - always combined with at least two NRTIs
• Baseline genotype testing recommended - identifies transmitted resistance
• Rapid switch after failure - continued efavirenz after virologic failure allows resistance accumulation
• Modern integrase inhibitor advantage - dolutegravir has much higher genetic barrier

📈 Baseline assessment checklist

• Complete blood count with differential and platelet count
• Comprehensive metabolic panel including hepatic enzymes, bilirubin, albumin, creatinine
• Estimated creatinine clearance
• Fasting lipid panel
• Fasting glucose or HbA1c
• HIV RNA quantitation and CD4 count
• HIV genotype resistance testing
• HBsAg, anti-HBc, anti-HBs (mandatory HBV screening before HIV therapy)
• HBV DNA if HBsAg positive or anti-HBc positive
• HCV antibody screening
• Hepatitis A serology and vaccination status
• Urinalysis
• Pregnancy testing where applicable; contraception counseling
• Baseline psychiatric assessment - depression screening (PHQ-2 or similar)
• Seizure history assessment
• Cardiovascular assessment including baseline ECG if risk factors
• Medication reconciliation for CYP450 interactions
• 25-OH vitamin D if risk factors

📅 On-therapy monitoring schedule

🎯 Virologic suppression endpoint

Successful HIV therapy is defined by sustained virologic suppression - HIV RNA under 50 copies/mL (or under 20 copies/mL on some assays). This should be achieved by week 12-24 of therapy and maintained indefinitely with continuous treatment. Suppression is the primary goal, and CD4 recovery follows over months to years. Ongoing monitoring confirms sustained suppression and detects rare rebound requiring investigation.

📦 Storage requirements

🗣️ Essential patient counseling points

Take every dose - HIV therapy is lifelong

Take Sustiva at bedtime once daily. HIV therapy is a lifelong commitment - do not stop even if you feel well. Missed doses can allow HIV replication and select resistance to efavirenz.

Bedtime timing and empty stomach

Take at bedtime on empty stomach (at least 2 hours after evening meal, water only for administration). This timing minimizes daytime CNS effects and prevents food-induced exposure increase.

Combination therapy - never alone

Sustiva must always be taken with two additional antiretrovirals (typically tenofovir + emtricitabine or lamivudine). Never take efavirenz alone for HIV. Atripla (single-tablet regimen) provides all three drugs in one tablet.

CNS effects expected initially

CNS effects (dizziness, vivid dreams, insomnia, difficulty concentrating) are common during first weeks - about half of patients experience them. Most improve substantially over 2-3 months as your body adapts. Be patient during adaptation.

Report severe mood changes immediately

Contact healthcare provider immediately for severe depression, suicidal thoughts, aggressive feelings, or unusual mental states. These are rare but serious effects requiring urgent evaluation. Sustiva may need to be discontinued.

Driving and safety caution

Use caution with driving, operating machinery, or performing tasks requiring full alertness during first weeks of therapy. Dizziness and concentration effects can affect safety.

Alcohol moderation

Alcohol can worsen CNS effects. Moderate or avoid alcohol especially during initial adaptation period.

Do not start new medications without checking

Efavirenz has many drug interactions through CYP3A4 induction. Inform all healthcare providers about HIV therapy. Check with pharmacist before starting any new prescription or over-the-counter medication.

False-positive cannabinoid drug screen

Efavirenz metabolites can cause false-positive results on urine cannabinoid drug screening. Confirmatory testing (GC-MS or LC-MS) distinguishes true cannabinoid use from efavirenz cross-reactivity. Inform employer or legal authorities about Sustiva use if drug testing is required.

Contraception if pregnancy possible

Efavirenz substantially reduces oral contraceptive effectiveness. Reliable alternative contraception (barrier methods with additional method, IUD, or long-acting reversible contraception) required for pregnancy prevention.

Not a cure

HIV therapy suppresses HIV replication but does not eliminate infection. Continued treatment maintains viral suppression. Patients should not expect symptoms alone to indicate treatment effectiveness - viral load monitoring provides objective assessment.

Ongoing transmission prevention

Patients on effective antiretroviral therapy with sustained viral suppression have negligible sexual transmission risk to partners (undetectable equals untransmittable, U=U). This reflects sustained viral suppression and requires ongoing adherence. Safe sex practices for other sexually transmitted infections remain important.

🚫 Absolute contraindications

Hypersensitivity to efavirenz

Prior severe hypersensitivity reaction (Stevens-Johnson syndrome, DRESS, toxic epidermal necrolysis) attributed to efavirenz is an absolute contraindication to rechallenge.

Concurrent contraindicated medications

Ergot alkaloids (ergotamine, dihydroergotamine, methylergonovine); midazolam (oral); triazolam; pimozide; cisapride (where available); St. John Wort - all contraindicated due to serious interaction potential.

Bepridil

Bepridil is contraindicated with efavirenz due to serious interaction potential and QT prolongation additive effects.

Severe hepatic impairment (Child-Pugh C)

Limited safety data in Child-Pugh C hepatic impairment. Efavirenz should not be used in this population without specialist input and typically alternative HIV therapy is preferred.

⚠️ Relative contraindications and precautions

Active severe psychiatric disorders

Active severe depression, psychosis, suicidal ideation, or history of psychiatric hospitalization warrant careful evaluation. Efavirenz can worsen or precipitate these conditions. Alternative HIV therapy (integrase inhibitor-based) is typically preferred.

Seizure history

Prior seizures or seizure disorder warrant specialist input. Anticonvulsant selection may need to accommodate efavirenz interactions. Alternative HIV therapy may be preferred.

Prior K103N or NNRTI resistance

Baseline genotype testing showing K103N or other NNRTI resistance mutations makes efavirenz inappropriate. Alternative HIV therapy required.

Concurrent voriconazole

Bidirectional interaction; efavirenz reduces voriconazole substantially while voriconazole increases efavirenz. Combined use is complicated. Dose adjustments possible but often alternative HIV therapy preferred.

Occupational or legal drug testing exposure

False-positive cannabinoid urine screening can create employment or legal complications. Patients in high-risk drug testing contexts may benefit from alternative HIV therapy.

Pregnancy planning

While efavirenz is not absolutely contraindicated in pregnancy per modern guidance, women planning pregnancy in the near future may benefit from dolutegravir-based therapy that is currently preferred first-line.

Substance use disorders

Active substance use disorders complicate efavirenz management due to interactions with methadone, drug testing considerations, and psychiatric effects. Individualized approach with addiction specialist input.

Concurrent QT-prolonging medications

Multiple QT-prolonging concurrent medications warrant baseline ECG and careful monitoring. Alternative HIV therapy without QT effects may be preferred.

Cognitive impairment

Baseline cognitive impairment can be worsened by efavirenz CNS effects. Alternative therapy typically preferred.